Z-SYMBOLS
March 3, 2025 | CRM, Daily JAM, Jubak Picks, Morning Briefing, Stock Alerts |
I’m selling Salesforce (CRM) out of my Jubak’s Picks Portfolio tomorrow, March 4. The position was up 22% as of the close on March 3 from my buy on June 22, 2024.I added the stock back in June because I think companies with existing product platform that can add AI to bring value to their customers is the next stage in monetizing AI. I still think that’s true but the trend is taking a bit longer to play out than a market increasingly impatient with AI profits is willing to pay up for.If we get the sell off that certainly now looks possible, I’d be more than happy to rebuy.
February 27, 2025 | Daily JAM, Jubak Picks, Long Term, Morning Briefing, NVDA, Top 50 Stocks |
Last night, in after hours trading, shares of Nvidia (NVDA), which had closed up 3.67% in the regular session, traded down a twitch, slipping by 0.04%. Today, Thursday, February 27, the shares started off in decent shape but then sold off all afternoon, closing down 8.48%. What was so disappointing about Nvidia’s results? And what should you do about this drop?
February 26, 2025 | Daily JAM, FCX, Jubak Picks, Morning Briefing, Stock Alerts, Top 50 Stocks |
President Donald Trump has ordered an investigation of copper imports in what is a first step toward potential tariffs on the metal. The move launches a process that Trump previously used to put tariffs on steel and aluminium, opening a new front in his trade war. We’re at the early stages in this effort but I think a copper tariff play is a reasonable buy right now–especially since coopper demand and copper prices are forecast to climb tariffs or no tariffs. The biggest winner would be Freeport-McMoRan (FCX), the largest producer of copper in the United States. I’ll adding shares of Freeport my Jubak Picks portfolio tomorrow, Thursday, February 27.
February 25, 2025 | Daily JAM, Jubak Picks, LLY, NVO |
Compounding pharmacies aren’t giving up their ability to create cheaper knockoff versions of Eli Lilly (LLY) and Novo Nordisk’s (NVO) GLP-1 weight loss drugs without a fight. On Friday the u.s. food and Drug Administration found that the shortage for Novo’s blockbuster GLP-1 treatments Ozempic, approved for diabetes, and Wegovy, approved for obesity, was over and that compounders would have to stop producing them in the next 60 to 90 days. Today,the Outsourcing Facilities Association (OFA) and Texas-based FarmaKeio Superior Custom Compounding filed a lawsuit in U.S. District Court in Fort Worth, Texas
February 25, 2025 | AAPL, Daily JAM, NVDA, Top 50 Stocks |
The Invesco QQQ ETF (QQQ), which tracks the tech-heavy Nasdaq 100 index (NDX), closed below its 50-day moving average on Monday for the first time in just over three weeks. The ETF was down another 0.83% as of 3:30 p.m. New York time on Tuesday.
February 24, 2025 | Daily JAM, Jubak Picks, MSFT, Top 50 Stocks |
In a week when Nvidia’s upcoming earnings report has all eyes on AI stocks, Microsoft (MSFT) has canceled some leases for U.S. data center capacity, according to TD Cowen.
OpenAI’s biggest backer has voided leases in the US totaling “a couple of hundred megawatts” of capacity—the equivalent of roughly two data centers.
February 24, 2025 | AAPL, Daily JAM, Morning Briefing |
In the first Trump Administration Apple (AAPL) avoided tariffs on its smartphones and on its Apple Watch made in China. This time around Apple may avoid the administration’s tariffs again, but the cost is a promise to spend $500 billion and hire 20,000 people in the United States over the next four years, and open a factory in Texas to make the machines that power the company’s push into artificial intelligence.
February 22, 2025 | Daily JAM, NVDA, Top 50 Stocks |
I expect the earnings report of the week will be Nvidia’s (NVDA) report after the close on Wednesday, February 26. For the fiscal quarter ending January 2025, the consensus EPS forecast is $0.79. The reported EPS for the same quarter last year was $0.49. Analysts expect NVIDIA’s earnings to grow 43.68% next year from $2.77 to $3.98 per share.
February 19, 2025 | Daily JAM, GDX, GDXJ, GLD, GOLD, Jubak Picks, Morning Briefing, NEM, Perfect Five-ETFs, Volatility |
Today Goldman Sachs Group raised its year-end target for gold to $3,100 an ounce. Central banks are buying gold at a faster than expected pace and flows into gold ETFs are accelerating.
February 14, 2025 | AAPL, ACAD, AGN, ALV, AMZN, AUY, BABA, BG, BGC, BHP, BMY, CHK, CMI, CNI, COH, CSCO, CX, Daily JAM, DD, DE, DHR, DXJR, EBAY, ENB, EUM, FB, FCX, FLR, FLS, FTV, GLD, Jubak Picks, MPC, OGXI, OKS, PEP, PFXF, POT, PXD, QCOM, RSPP, RYN, SDRL, SFTBY, SH, SLB, SPWR, Videos, Volatility |
Today’s Hot Money Moves NOW is China Buys More Gold. Gold seems like a good asset to own right now but it’s also trading at record highs. So while gold is safe, especially if inflation goes up, how much higher do you expect gold to go? One thing to look at it is who is emerging as a buyer. Central banks have been buying gold to hedge risks and diversify, which has contributed to the record highs. Recently, the Chinese government announced that 10 big Chinese insurance companies will now be allowed to put up to 1% of their portfolios into gold. This hasn’t been allowed in the past and will provide about $27 billion for new gold buying. This is also just another sign that countries and businesses are looking to hedge risk by buying gold and it’s one of the safer places to be in an uncertain market.
February 13, 2025 | AG, Daily JAM, Volatility, WPM |
In the current market environment, with uncertainty running rampant and risk climbing, I want to find hedges against a downturn in U.S. stocks. Gold remains an attractive option even though it is trading near its nominal all-time high near $2900 an ounce. I think systemic risk–the odds that something fundamental will go wrong somewhere with the United States, China, and the European Union (through its exposure to Italy) are all worry hot spot–is on the rise. In the U.S. market alone, I see higher risk of a nasty mix higher inflation, slower growth, higher interest rates, and bigger government deficits.
February 12, 2025 | Daily JAM, ISRG, Top 50 Stocks, Videos |
Today’s Quick Pick is Intuitive Surgical (ISRG). While 2024 was a good year for the market, it wasn’t so great for the healthcare. The sector was down about .04%. Moderna was down 60%, CVS Health was down 50% and Walgreens was down 55%–but there were a few big winners. Intuitive Surgical, maker of the Da Vinci Robotic Surgical System, was the best performing healthcare stock in 2024. The stock went up 54.7% in 2024 and it’s gone up another 11.7% so far in 2025. At the moment, Morningstar says the stock is trading at 67% premium, with a high PE of around 80, so I’d suggest waiting to buy on a dip. I like this company because it’s growing revenue steadily, around 10% a year. I believe there is a good chance at getting a substantial market dip in 2025, and if that happens, take a look at this great long-term, steady performer in the healthcare sector. The stock has been a member of my long-term 50 Stocks Portfolio since January 28, 2019. the shares are up 257% since then as of the close on February 10.
